Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Cellectis S.A. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 36 | 31 | −5 |
| Shares | 14.0M | 11.5M | −2.53M (−18.0%) |
| Value | $27.6M | $18.1M | −$9.45M (−34.3%) |
New holders (2)
Institutions that held Cellectis S.A. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 4,035 | $6.38K | 0.00% |
| Qube Research & Technologies Ltd | 40 | $63 | 0.00% |
Sold out (7)
Institutions that held Cellectis S.A. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Bpifrance SA | 2,186,960 | $4.30M |
| Envestnet Asset Management Inc | 27,841 | $54.8K |
| One68 Global Capital, LLC | 11,000 | $21.6K |
| Assetmark, Inc | 2,721 | $5.35K |
| Parallel Advisors, LLC | 500 | $984 |
| Russell Investments Group, Ltd. | 98 | $193 |
| Ronald Blue Trust, Inc. | 48 | $0 |